- Potential for one-time transformative treatments for severe genetic and orphan diseases
- Encouraging clincial safety and efficacy data in beta thalassemia and CCALD with growing clinical pipeline
- Industrialized gene delivery platform across people, production, development, and deployment
…and much more!
Get your copy here!
If you’re interested in learning more about how Bluebirdbio is transforming the lives of patients with severe genetic disorders , attend Stem Cells & Regenerative Medicine Congress USA 2015 September 2-3 in Washington, DC.